Multiplex Detection of Rare Mutations by Picoliter Droplet Based Digital PCR: Sensitivity and Specificity Considerations

PLoS ONE

Volumn 11, Issue 7, 2016, Pages

  Zonta, Eleonora ^a   Garlan, Fanny ^a   Pécuchet, Nicolas ^a,b   Perez Toralla, Karla ^a   Caen, Ouriel ^a   Milbury, Coren ^c   Didelot, Audrey ^a   Fabre, Elizabeth ^a,b   Blons, Hélène ^a,b   Laurent Puig, Pierre ^a,b   Taly, Valérie ^a  

^a University of Sorbonne Paris la Cité   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c Raindance Technologies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PROTEIN P53; EGFR PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; PROTEIN P21; TP53 PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; DIAGNOSTIC KIT; DIGITAL POLYMERASE CHAIN REACTION; EGFR GENE; FEMALE; GENE CONTROL; GENE DELETION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; KRAS GENE; LUNG CANCER; MALE; MUTATIONAL ANALYSIS; NEOPLASM; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMERASE CHAIN REACTION SYSTEM; SENSITIVITY AND SPECIFICITY; TP53 GENE; DNA MUTATIONAL ANALYSIS; GENETICS; LUNG TUMOR; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATION; PATHOLOGY; PROCEDURES;

DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; HUMANS; LUNG NEOPLASMS; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATION; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, EPIDERMAL GROWTH FACTOR; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84978657930     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0159094     Document Type: Article

References (38)

1. Huggett JF, Foy CA, Benes V, Emslie K, Garson JA, Haynes R, et al. The digital MIQE guidelines: Minimum Information for Publication of Quantitative Digital PCR Experiments. Clinical chemistry. 2013; 59 (6):892-902. Epub 2013/04/11. doi: 10.1373/clinchem.2013.206375 PMID: 23570709.
2. Vogelstein B, Kinzler KW. Digital PCR. Proc Natl Acad Sci U S A. 1999; 96(16):9236-41. Epub 1999/ 08/04. PMID: 10430926; PubMed Central PMCID: PMC17763.
3. Sykes PJ, Neoh SH, Brisco MJ, Hughes E, Condon J, Morley AA. Quantitation of targets for PCR by use of limiting dilution. BioTechniques. 1992; 13(3):444-9. Epub 1992/09/01. PMID: 1389177.
4. Taly V, Pekin D, El Abed A, Laurent-Puig P. Detecting biomarkers with microdroplet technology. Trends Mol Med. 2012; 18(7):405-16. Epub 2012/06/26. doi: 10.1016/j.molmed.2012.05.001 PMID: 22727782.
5. Laurent-Puig P, Pekin D, Normand C, Kotsopoulos SK, Nizard P, Perez-Toralla K, et al. Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy. Clin Cancer Res. 2015; 21(5):1087-97. Epub 2014/09/25. doi: 10. 1158/1078-0432.CCR-14-0983 PMID: 25248381.
6. Watanabe M, Kawaguchi T, Isa SI, Ando M, Tamiya A, Kubo A, et al. Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non-Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR. Clin Cancer Res. 2015. Epub 2015/04/18. doi: 10.1158/1078-0432.CCR-14-2151 PMID: 25882755.
7. Guttery DS, Page K, Hills A, Woodley L, Marchese SD, Rghebi B, et al. Noninvasive Detection of Activating Estrogen Receptor 1 (ESR1) Mutations in Estrogen Receptor-Positive Metastatic Breast Cancer. Clinical chemistry. 2015; 61(7):974-82. Epub 2015/05/17. doi: 10.1373/clinchem.2015.238717 PMID: 25979954.
8. Taly V, Pekin D, Benhaim L, Kotsopoulos SK, Le Corre D, Li X, et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clinical chemistry. 2013; 59(12):1722-31. Epub 2013/08/14. doi: 10.1373/clinchem.2013.206359 PMID: 23938455.
9. Wang Q, Yang X, He Y, Ma, Lin, Fu P, et al. Droplet Digital PCR for Absolute Quantification of EML4-ALK Gene Rearrangement in Lung Adenocarcinoma. J Mol Diagn. 2015. Epub 2015/07/06. doi: 10. 1016/j.jmoldx.2015.04.002 PMID: 26142544.
10. Perez-Toralla K, Pekin D, Bartolo JF, Garlan F, Nizard P, Laurent-Puig P, et al. [Digital PCR compartmentalization I. Single-molecule detection of rare mutations]. Medecine sciences: M/S. 2015; 31(1):84-92. Epub 2015/02/07. doi: 10.1051/medsci/20153101017 PMID: 25658735.
11. Caen O, Nizard P, Garrigou S, Perez-Toralla K, Zonta E, Laurent-Puig P, et al. [Digital PCR compartmentalization II. Contribution for the quantitative detection of circulating tumor DNA]. Medecine sciences: M/S. 2015; 31(2):180-6. Epub 2015/03/07. doi: 10.1051/medsci/20153102015 PMID: 25744265.
12. Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clinical chemistry. 2015; 61(1):112-23. Epub 2014/11/13. doi: 10.1373/clinchem.2014.222679 PMID: 25388429.
13. Francis G, Stein S. Circulating Cell-Free Tumour DNA in the Management of Cancer. Int J Mol Sci. 2015; 16(6):14122-42. Epub 2015/06/24. doi: 10.3390/ijms160614122 PMID: 26101870; PubMed Central PMCID: PMC4490543.
14. Tsao SC, Weiss J, Hudson C, Christophi C, Cebon J, Behren A, et al. Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations. Scientific reports. 2015; 5:11198. Epub 2015/06/23. doi: 10.1038/srep11198 PMID: 26095797; PubMed Central PMCID: PMC4476039.
15. http://www.who.int.
16. Douillard JY, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G, et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2014; 9(9):1345-53. Epub 2014/08/15. doi: 10.1097/JTO.0000000000000263 PMID: 25122430; PubMed Central PMCID: PMC4224589.
17. Nishiyama A, Katakami N, Yoshioka H, Iwasaku M, Korogi Y, Hata A, et al. Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer. Lung Cancer. 2015. Epub 2015/07/ 05. doi: 10.1016/j.lungcan.2015.06.017 PMID: 26141215.
18. Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol. 2013; 31(31):3987-96. Epub 2013/10/09. doi: 10.1200/JCO.2012.45.2029 PMID: 24101047; PubMed Central PMCID: PMC3805932.
19. Massarelli E, Johnson FM, Erickson HS, Wistuba II, Papadimitrakopoulou V. Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance. Lung Cancer. 2013; 80(3):235-41. Epub 2013/03/15. doi: 10.1016/j.lungcan.2013.01.018 PMID: 23485129.
20. Yung TK, Chan KC, Mok TS, Tong J, To KF, Lo YM. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res. 2009; 15(6):2076-84. Epub 2009/03/12. doi: 10.1158/1078-0432.CCR-08-2622 PMID: 19276259.
21. http://www.mycancergenome.org.
22. Juchum M, Gunther M, Laufer SA. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy. 2015; 20:12-28. Epub 2015/05/30. doi: 10.1016/j.drup.2015.05.002 PMID: 26021435.
23. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008; 26(3):374-9. Epub 2008/01/19. doi: 10.1200/JCO.2007.12.5906 PMID: 18202412.
24. Tougeron D, Lecomte T, Pages JC, Villalva C, Collin C, Ferru A, et al. Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2013; 24(5):1267-73. Epub 2013/01/08. doi: 10.1093/annonc/mds620 PMID: 23293113.
25. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006; 66(8):3992-5. Epub 2006/ 04/19. doi: 10.1158/0008-5472.CAN-06-0191 PMID: 16618717.
26. Zheng D, Wang R, Zhang Y, Pan Y, Cheng X, Cheng C, et al. The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations. OncoTargets and therapy. 2016; 9:833-43. Epub 2016/03/10. doi: 10.2147/OTT.S96834 PMID: 26955281; PubMed Central PMCID: PMC4768896.
27. Huang J, Lohr JM, Nilsson M, Segersvard R, Matsson H, Verbeke C, et al. Variant Profiling of Candidate Genes in Pancreatic Ductal Adenocarcinoma. Clinical chemistry. 2015; 61(11):1408-16. Epub 2015/09/18. doi: 10.1373/clinchem.2015.238543 PMID: 26378065.
28. Didelot A, Le Corre D, Luscan A, Cazes A, Pallier K, Emile JF, et al. Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. Experimental and molecular pathology. 2012; 92(3):275-80. Epub 2012/03/20. doi: 10.1016/j. yexmp.2012.03.001 PMID: 22426079.
29. Duffy MJ, Synnott NC, McGowan PM, Crown J, O'Connor D, Gallagher WM. p53 as a target for the treatment of cancer. Cancer treatment reviews. 2014; 40(10):1153-60. Epub 2014/12/03. doi: 10.1016/ j.ctrv.2014.10.004 PMID: 25455730.
30. Li J, Yang L, Gaur S, Zhang K, Wu X, Yuan YC, et al. Mutants TP53 p.R273H and p.R273C but not p. R273G enhance cancer cell malignancy. Hum Mutat. 2014; 35(5):575-84. Epub 2014/03/29. doi: 10. 1002/humu.22528 PMID: 24677579.
31. Zhang Y, Zhang YJ, Zhao HY, Zhai QL, Zhang Y, Shen YF. The impact of R213 mutation on p53-mediated p21 activity. Biochimie. 2014; 99:215-8. Epub 2014/01/05. doi: 10.1016/j.biochi.2013.12.017 PMID: 24384472.
32. Zonta E, Nizard P, Taly V. Assessment of DNA Integrity, Applications for Cancer Research. Advances in clinical chemistry. 2015; 70:197-246. Epub 2015/08/02. doi: 10.1016/bs.acc.2015.03.002 PMID: 26231488.
33. Milbury CA. Determining lower limits of detection of digital PCR assays for cancer-related gene mutations. Biomolecular Detection and Quantification. 2014;Volume 1(Issue 1):Pages 8-22.
34. Alix-Panabieres C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clinical chemistry. 2013; 59(1):110-8. Epub 2012/09/28. doi: 10.1373/clinchem.2012.194258 PMID: 23014601.
35. Zheng D, Ye X, Zhang MZ, Sun Y, Wang JY, Ni J, et al. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. Scientific reports. 2016; 6:20913. Epub 2016/02/13. doi: 10.1038/srep20913 PMID: 26867973; PubMed Central PMCID: PMC4751431.
36. Yang X, Zhuo M, Ye X, Bai H, Wang Z, Sun Y, et al. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer. Oncotarget. 2016. Epub 2016/03/19. doi: 10.18632/ oncotarget.8021 PMID: 26989078.
37. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Science translational medicine. 2014; 6 (224):224ra24. Epub 2014/02/21. doi: 10.1126/scitranslmed.3007094 PMID: 24553385; PubMed Central PMCID: PMC4017867.
38. Zhong Q, Bhattacharya S, Kotsopoulos S, Olson J, Taly V, Griffiths AD, et al. Multiplex digital PCR: breaking the one target per color barrier of quantitative PCR. Lab Chip. 2011; 11(13):2167-74. Epub 2011/05/18. doi: 10.1039/c1lc20126c PMID: 21584334.